BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Army
Deloitte
Johnson and Johnson
Dow
Argus Health
Healthtrust
UBS
Boehringer Ingelheim
Express Scripts

Generated: January 22, 2018

DrugPatentWatch Database Preview

ALIMTA Drug Profile

« Back to Dashboard

When do Alimta patents expire, and what generic alternatives are available?

Alimta is a drug marketed by Lilly and is included in one NDA. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has thirty-one patent family members in twenty-five countries.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pemetrexed disodium profile page.
Drug patent expirations by year for ALIMTA
Pharmacology for ALIMTA

US Patents and Regulatory Information for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-002 Sep 7, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-001 Feb 4, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-002 Sep 7, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-001 Feb 4, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-002 Sep 7, 2007 ➤ Subscribe ➤ Subscribe
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-001 Feb 4, 2004 ➤ Subscribe ➤ Subscribe
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-001 Feb 4, 2004 ➤ Subscribe ➤ Subscribe
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-002 Sep 7, 2007 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALIMTA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe 10/6/2016
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe 6/27/2012
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe 7/1/2008
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2/4/2008

Non-Orange Book US Patents for ALIMTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,996,206 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives ➤ Subscribe
5,028,608 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives ➤ Subscribe
5,248,775 Pyrrolo(2,3-d)pyrimidines ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ALIMTA

Supplementary Protection Certificates for ALIMTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432677/01 Switzerland ➤ Subscribe FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0181 Netherlands ➤ Subscribe 300181, 20101210, EXPIRES: 20151209
C/GB05/011 United Kingdom ➤ Subscribe PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
147 Luxembourg ➤ Subscribe 91147, EXPIRES: 20151210
2005 00008 Denmark ➤ Subscribe
2005 Austria ➤ Subscribe PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Colorcon
Medtronic
Fuji
Farmers Insurance
Chubb
Cantor Fitzgerald
Chinese Patent Office
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot